Expression of MS4A and TMEM176 genes in human B lymphocyte

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  Zuccolo, Jonathan ^a   Deng, Lili ^a   Unruh, Tammy L ^a   Sanyal, Ratna ^a   Bau, Jeremy A ^a   Storek, Jan ^a,b   Demetrick, Douglas J ^a,b,c   Luider, Joanne M ^c   Auer Grzesiak, Iwona A ^b,c   Mansoor, Adnan ^b,c   Deans, Julie P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

B lymphocytes; CD20; CLL; MS4A; TMEM176

Indexed keywords

CD20 ANTIGEN; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD20 GENE; CELL FUNCTION; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MIDDLE AGED; MS4A GENE; REAL TIME POLYMERASE CHAIN REACTION; TMEM176 GENE; TONSIL; VERY ELDERLY;

EID: 84883726328     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00195     Document Type: Article

References (34)

1. Ishibashi K, Suzuki M, Sasaki S, Imai M. Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor. Gene (2001) 264(1):87-93. doi:10.1016/S0378-1119(00)00598-9
2. Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics (2001) 72(2):119-27. doi:10.1006/geno.2000.6472
3. Zuccolo J, Bau J, Childs SJ, Goss GG, Sensen CW, Deans JP. Phylogenetic analysis of the MS4A and TMEM176 gene families. PLoS ONE (2010) 5(2):e9369. doi:10.1371/journal.pone.0009369
4. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem (2008) 283(27):18545-52. doi:10.1074/jbc. M800784200
5. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem (2003) 278(43):42427-34. doi:10.1074/jbc. M308802200
6. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest (2010) 120(1):214-22. doi:10.1172/JCI40231
7. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int (2006) 19(8):621-8. doi:10.1111/j.1432-2277.2006.00345.x
8. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant (2006) 6(5 Pt 1):859-66. doi:10.1111/j.1600-6143.2006.01288.x
9. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2010) 95(1):135-43. doi:10.3324/haematol.2008.001628
10. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood (2002) 99(9):3256-62. doi:10.1182/blood. V99.9.3256
11. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 177(1):362-71.
12. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood (2011) 118(2):358-67. doi:10.1182/blood-2010-09-305847
13. Cragg MS. CD20 antibodies: doing the time warp. Blood (2011) 118(2):219-20. doi:10.1182/blood-2011-04-346700
14. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem (1998) 273(1):344-8. doi:10.1074/jbc.273.1.344
15. Li H, Ayer LM, Polyak MJ, Mutch CM, Petrie RJ, Gauthier L, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem (2004) 279(19):19893-901. doi:10.1074/jbc. M400525200
16. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid 'rafts'. Blood (2003) 101:1045-52. doi:10.1182/blood-2002-06-1761
17. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res (1989) 49(17):4906-12.
18. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood (1994) 83(5):1390-7.
19. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 115(25):5191-201. doi:10.1182/blood-2010-01-263533
20. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol (1993) 121(5):1121-32. doi:10.1083/jcb.121.5.1121
21. Howie D, Nolan KF, Daley S, Butterfield E, Adams E, Garcia-Rueda H, et al. MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation. J Immunol (2009) 183(7):4197-204. doi:10.4049/jimmunol.0901070
22. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol (1992) 40(4):259-63. doi:10.1002/ajh.2830400404
23. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 98(12):3383-9. doi:10.1182/blood. V98.12.3383
24. Sarro SM, Unruh TL, Zuccolo J, Sanyal R, Luider JM, Auer-Grzesiak IA, et al. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. Leuk Res (2010) 34(12):1670-3. doi:10.1016/j.leukres.2010.06.031
25. Zuccolo J, Unruh TL, Deans JP. Efficient isolation of highly purified tonsil B lymphocytes using RosetteSep with allogeneic human red blood cells. BMC Immunol (2009) 10:30. doi:10.1186/1471-2172-10-30
26. PfafflMW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 29(9):e45. doi:10.1093/nar/29.9.e45
27. Bangur CS, Johnson JC, Switzer A, Wang YH, Hill B, Fanger GR, et al. Identification and characterization of L985P, a CD20 related family member overexpressed in small cell lung carcinoma. Int J Oncol (2004) 25(6):1583-90.
28. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature (2011) 473 (7347):337-42. doi:10.1038/nature10098
29. Donato JL, Ko J, Kutok JL, Cheng T, Shirakawa T, Mao XQ, et al. Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest (2002) 109(1):51-8. doi:10.1172/JCI200214025
30. Sala-Valdes M, Ailane N, Greco C, Rubinstein E, Boucheix C. Targeting tetraspanins in cancer. Expert Opin Ther Targets (2012) 16(10):985-97. doi:10.1517/14728222.2012.712688
31. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs (2009) 10(12):1383-90.
32. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood (2007) 110(7):2569-77. doi:10.1182/blood-2006-12-062927
33. van Spriel AB. Tetraspanins in the humoral immune response. Biochem Soc Trans (2011) 39(2):512-7. doi:10.1042/BST0390512
34. Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia (2012) 26(3):546-9. doi:10.1038/leu.2011.233